Top Markets
#1 Audiera Audiera +38.20%
#2 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +33.00%
#3 Bitcoin Cash Bitcoin Cash +32.56%
#4 Tutorial Tutorial +30.97%
#5 Fabric Protocol Fabric Protocol +30.73%
#6 Prom Prom +28.96%
#7 GALA GALA +27.57%
#8 Arowana Arowana +27.09%
#9 Ethena Staked ENA Ethena Staked ENA +26.37%
#10 Useless Coin Useless Coin +24.76%
Coin of the day
Audiera Audiera
Settings
Language
ENGLISH
Currency
USD
Theme
ERYTECH Pharma S.A. ERYTECH Pharma S.A.

ERYTECH Pharma S.A.

ERYP
Rank in Stocks #24699
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on... ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells. These treatments target various types of cancer and rare (orphan) diseases, with the company operating in both France and the United States. Its primary experimental drug, eryaspase, is currently undergoing Phase 3 clinical trials for patients battling second-line pancreatic cancer. Furthermore, this candidate is also in Phase 2 development for triple-negative breast cancer and for individuals with second-line acute lymphoblastic leukemia. The company is additionally advancing erymethionase, a preclinical-stage product. This candidate utilizes methionine-gamma-lyase, encased within red blood cells, to specifically address cancers that are dependent on methionine for growth. Established in 2004, ERYTECH Pharma's corporate headquarters are situated in Lyon, France.
Share Price
$0.95011029
Last synced: 2023-06-28
Market Cap
$57.72M
Change (1 day)
8.53%
Change (1 year)
0.00%
Country
FR
Trade ERYTECH Pharma S.A. (ERYP)

Category

Healthcare
Revenue for ERYTECH Pharma S.A. (ERYP)
Revenue in Aug 2026 TTM: 0
According to ERYTECH Pharma S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for ERYTECH Pharma S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH